medigraphic.com
ISSN 1029-3043 (Electronic)

2022, Number 3

<< Back Next >>

Medicentro 2022; 26 (3)

COVID-19, its relationship with autoimmune diseases

Rivera TR, Rivera CT, Tirado SS

Language: Spanish
References: 22
Page: 673-690
PDF size: 637.17 Kb.


ABSTRACT

Introduction: COVID-19, in addition to spreading from person to person, threatens the economic and political stability of nations and has caused lethal respiratory infections in humans. This may be relevant when dealing with infection in an immunocompromised patient, potentially protected by a weaker immune response against infection.
Objective: to describe the relationship of COVID-19 with some autoimmune diseases.
Methods: the analysis-synthesis method, as well as the bibliographic and documentary analysis were used; the search engines were Hinari, Pubmed, ClinicalKey, SciELO regional, SciELO Cuba and Google Scholar.
Conclusions: patients with autoimmune diseases are classified as risk patients. In case of being confirmed with COVID-19, most of their medications should be suspended and only maintain their treatments with hydroxychloroquine and IL-6 inhibitors in case of autoimmune arthritis, and glatiramer acetate in multiple sclerosis. These people must strictly follow the measures directed by the health authorities.


REFERENCES

  1. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ECA2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell [internet]. mar. 2020 [citado 13 jun. 2020];181(2):[aprox. 9.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32142651/1.

  2. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med [internet]. 2020 [citado 13 jun. 2020];26(4):[aprox. 2 p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32284615/2.

  3. Buschiazzo A. COVID-19: cómo cuidar a los pacientes con enfermedades autoinmunes [internet]. Argentina: Infobae; 2020 [citado 13 jun. 2020]. Disponible en: https://www.infobae.com/salud/2020/04/16/Covid-19-como-cuidar-a-los-pacientes-con-enfermedades-autoinmunes/ [ Links ]

  4. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol [internet]. 2020 [citado 13 jun. 2020];5(7):[aprox. 9 p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32219363/4.

  5. Serra Valdés MA. Infección respiratoria aguda por COVID-19: una amenaza evidente. Rev Haban Cienc Méd [internet]. 2020 [citado 13 jun. 2020];19(1):[aprox. 4 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1729-519X20200001000015.

  6. Zavala-Flores E, Salcedo-Matienzo J, Berrocal Kasay A. COVID-19 y enfermedades autoinmunes: población con alto riesgo para desarrollar enfermedad severa. Acta Méd Perú [internet]. 2020 [citado 31 oct. 2021];37(3) Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1728-591720200003004076.

  7. González Costa M, Padrón González AA. Factores etiopatogénicos de las enfermedades autoinmunes en el siglo XXI. Rev Cubana Invest Bioméd [internet]. 2021 [citado 31 oct. 2021];40(1):[aprox. 10 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-030020210001000197.

  8. Xu X, Chen P, Wan J, Feng J, Zhou H, Li X, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Sci Life [internet]. 2020 [citado 31 oct. 2020];63(3):[aprox. 3 p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32009228/8.

  9. Siddiqi HK, Mehra MR. Covid-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Hear Long Transplant [internet]. 2020 [citado 31 oct. 2020];39(5):[aprox. 2 p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32362390/9.

  10. Fung Sy, Yueng KS, Ye ZW, Chan CP, Jin DY. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defense: lessons from other pathogenic viruses. Emerg Microbes Infect [internet]. 2020 [citado 30 oct. 2020];9(1):[aprox. 12 p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32172672/10.

  11. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factor for mortality of adult inpatients with Covid-19 in Wuhan, China: a retrospective cohort study. Lancet [internet]. 2020 [citado 30 oct. 2020];395(10229):[aprox. 8 p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32171076/11.

  12. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiological Characteristics of 2143 Pediatric Patients with 2019 Coronavirus Disease in China. J Emerg Med [internet]. 2020 [citado 13 jun. 2020];58(4):[aprox. 1 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266747/12.

  13. Liu W, Zhang Q, Chen J, Xian R, Song H, Shu S, et al. Detection of Covid-19 in Children in Early January 2020 in Wuhan, China. N Engl J Med [internet]. 2020 [citado 13 jun 2020];382(14):[aprox. 1 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121643/13.

  14. Fundación IO. Coronavirus COVID-19. ¿Quiénes son los pacientes de riesgo? [internet]. España: Fundación IO; 2020 [citado 13 de junio de 2020]. Disponible en: https://fundacionio.com/2020/03/10/coronavirus-Covid-19-quienes-son-los-pacientes-de-riesgo/14.

  15. Coronavirus y pacientes con enfermedades reumáticas. Sociedad Española de Reumatología (SER) [internet]. España: SER; 2020 [citado 13 jun 2020]. Disponible en: https://www.ser.es/el-coronavirus-Covid-19-y-los-pacientes-con-enfermedades-reumaticas/15.

  16. Caraballoso E. Medicamentos cubanos contra la Covid-19 (II) [internet]. La Habana: Ministerio de Salud Pública; 2020 [citado 14 de junio] Disponible en: https://oncuba.news.com/coronavirus/medicamentos-cubanos-contra-la-Covid-19 [ Links ]

  17. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med [internet]. 2020 [citado 13 de junio de 2020];19:[aprox. 1 p.]. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/3210901317.

  18. Mehta P, Mcauley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet [internet]. 2020 [citado 30 oct 2020];67(36):[aprox. 1 p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32192578/18.

  19. Agencia Española de Medicamentos y Productos Sanitarios. Ficha técnica Copaxone [internet]. España: Ministerio de sanidad, política social e igualdad; 2020 [citado 14 jun. 2020]. Disponible en: https://cima.aemps.es/cima/pdfs/es/ft/65983/65983_ft.pdf [ Links ]

  20. Launay M, Baudouin V, Guillemain R, Maisin A, Flodrops H, Douez E, et al. Leflunomide for BKvirus: report of seven kidney-transplanted children. Int J Organ Transplant Med [internet]. 2018 [citado 30 oct. 2020];9(4):[aprox. 5 p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30863521/20.

  21. Comi G, Freedman MS, Kappos L, O´Connor P, Miller AE, Olsson TP, et al. Pooled safety and tolerability data from four placebo-controlled teriflunomida studies and extensions. Mult Scler Relat Disord [internet]. 2016 [citado 30 oct. 2020];5:[aprox. 6 p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26856952/21.

  22. Costa-Frossard L, Moreno-Torres I, Meca-Lallana V, García-Domínguez JM. Documento EMCAM (Esclerosis Múltiple Comunidad Autónoma de Madrid) para el manejo de pacientes con esclerosis múltiple durante la pandemia de SARS-CoV-2. Rev Neurol [internet]. 2020 [citado 30 oct. 020];70(9):[aprox. 11 p.]. Disponible en: http://www.revibiomedica.sld.cu/index.php/ibi/article/view/844/99522.




2020     |     www.medigraphic.com